ClinicalTrials.gg
RecruitingNCT07488247C6-PDT in DFUUpdated Apr 7, 2026

Phase IIb and III Safety and Efficacy Study Chlorin E6 Gel Photodynamic Therapy for Diabetic Foot Ulcers:

A Phase 3 interventional study of Chlorin E6 Gel in Diabetic Foot Ulcer (DFU), sponsored by United Medical and Dental College. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by United Medical and Dental College · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Diabetic Foot with a site in Pakistan — 5 open to participants now, 7 under way, 1 of them phase 3. Diabetic Foot · Pakistan.

Planned enrollment
Largest of 16
300 · median 94
Started
2026
with 3 others
Phase 3
Only one
of the 17
Registered
13th of 17
by date

Among the 17 studies in Diabetic Foot with a site in Pakistan, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 3, and was the 13th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

5 of the 17 studies in Diabetic Foot with a site in Pakistan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetic Foot with a site in Pakistan, or all of them as a file.
02

Study summary

Protocol No. CHLORIN E6-IIB/III-01/Protocol/1.1 Title:Single-Centre, open-labeled, randomized, Phase IIb and Phase III clinical studies to evaluate the safety, tolerability, and efficacy of Chlorin E6 (Gel Formation) as a photosensitizing agent for the management of Diabetic Foot Ulcers with Photodynamic Therapy.

Sponsor Synverdis GmbH, Heidelberg, Germany. Study Phase: Phase IIb(Completed) \& Phase III(Ongoing) Indication : Diabetic Foot Ulcers Study Population: This study will be conducted on diabetic participants who are 18 years of age or older, with a documented diagnosis of diabetes and foot ulceration that has been present for at least 4 weeks.

Sample Size of Phase IIb: 30 participants were enrolled. Phase III: 300 participants will be enrolled. Intervention Investigational Product: Chlorin E6 gel Specification: 1.0 mg/cm2 of Chlorin E6 1% W/V in gel-form Formulation: Gel Storage and Transportation: Store and ship at 2\~8°C, avoiding freezing.

Standard of Care Treatment:

a. Surgical Intervention: Debridement of the wound will be performed for all the participants. b. Medical Intervention: i. Antibiotics: Targeted to aerobic Gram-positive cocci in mild to moderate infections.

- Moxifloxacin

  • Linezolid
  • Co-Amoxiclav
  • Piperacillin + Tazobactam
  • Clindamycin

Dosage \& Application Patients will receive 1.0 mg/cm2 of Chlorin E6 1% W/V in gel form by local application on the ulcer. Approximately 30 minutes after the study drug administration, the ulcer will be washed thoroughly with normal saline. Then it will be illuminated with light at 660 to 670 nm from an approved laser source with a calculated light dose of 100 J/cm2. Light will be applied to the entire surface of the ulcer for 11 minutes. The wound will then be illuminated with UV light to assess the effectiveness of Photodynamic Therapy (PDT) and a further 11 minutes of therapy will be carried out if required.

Study Objectives Phase IIb:

Primary Objectives:

  1. To determine the safety and efficacy of a local Chlorin E6-mediated Photodynamic Therapy in patients with diabetic foot ulcers.
  2. To determine the effect of Chlorin E6 on the healing of diabetic foot ulcers defined by a reduction in size and depth of the ulcer.
  3. To compare the efficacy and healing rates of Diabetic foot ulcers with and without local Chlorin E6-mediated Photodynamic Therapy along with standard of care (SOC) management.
  4. To determine the eradication ratio of pathogenic bacteria through the synergistic effect of local Chlorin E6-mediated Photodynamic Therapy.

Phase III:

Primary Objectives:

  1. To determine the safety and efficacy of a local Chlorin E6-mediated Photodynamic Therapy in patients with diabetic foot ulcers.
  2. To determine the effect of Chlorin E6 on the healing of diabetic foot ulcers defined by reduction in size and depth of ulcer.
  3. To compare the efficacy and rates of healing of Diabetic Foot Ulcer (DFU) with and without local Chlorin E6-mediated Photodynamic Therapy along with standard of care management.
  4. To determine the eradication ratio of pathogenic bacteria through the synergistic effect of local Chlorin E6-mediated Photodynamic Therapy.

Secondary Objectives:

  1. To determine the rates of recurrence of diabetic foot ulcers during 6 months after local Chlorin E6-mediated Photodynamic Therapy.
  2. To determine the reduction in rates of amputation during 6 months after local Chlorin E6-mediated Photodynamic Therapy.

    Study Endpoints Phase IIb:

    Primary endpoints:

    Safety:

    • Solicited local and systemic AEs within 30 minutes and 7 days after product administration/application;

    Secondary endpoints:

    Safety:

    • Unsolicited AEs within 28 days after product administration/application;
    • SAEs throughout 3 months after product administration/application;
    • Abnormal laboratory value analysis on Day 14 after product administration/application;

    Efficacy:

    • No growth on culture of wound base swab at 1 week after product administration/ application.
    • Rate of healing > 15 % in 1 week or >50% in 1 month

    Phase III:

    Primary endpoints:

    Safety:

    • Solicited local and systemic AEs within 30 minutes and 7 days after product administration/application;

    Secondary endpoints:

    Safety:

    • Unsolicited AEs within 28 days after product administration/application;
    • SAEs throughout 6 months after product administration/application;
    • Abnormal laboratory value analysis on Day 14 after product administration/application;

    Efficacy:

    • No growth on culture of wound base swab at 1 week after product administration/ application.
    • Rate of healing > 15 % in 1 week or >50% in 1 month.

    Phase IIB of this trial is completed and screening of Phase III is started on 31-Mar-2026.

Read the detailed description

This is a single-centre, open-label, randomized Phase IIb and Phase III clinical study designed to evaluate the safety, tolerability, and efficacy of Chlorin E6 gel as a photosensitizing agent in the management of diabetic foot ulcers (DFU) using Photodynamic Therapy (PDT).

Eligible participants are adults (≥18 years) with a documented diagnosis of diabetes and chronic foot ulceration present for at least 4 weeks. In Phase IIb, 30 participants were enrolled; Phase III will include 300 participants.

The investigational product, Chlorin E6 gel (1% W/V, 1.0 mg/cm²), is applied locally to the ulcer. After 30 minutes, the ulcer is washed with saline and illuminated with red light (660-670 nm) at a dose of 100 J/cm² for 11 minutes. If required, a second illumination is performed. Standard of care (SOC) management-including wound debridement, targeted antibiotics, and optimized glycemic control-is provided to all participants.

Primary objectives are to assess safety and efficacy of Chlorin E6-mediated PDT, evaluate ulcer healing (size and depth reduction), compare healing rates with SOC alone, and determine bacterial eradication. Secondary objectives include recurrence rates and reduction in amputations within 6 months.

Endpoints include solicited local/systemic adverse events (AEs), unsolicited AEs, serious adverse events (SAEs), abnormal laboratory values, wound culture results, and healing rates (>15% at 1 week or >50% at 1 month).

The study lasted 3 months per participant in Phase IIb (completed) and 6 months per participant in Phase III, was started in March 2026.

03

Conditions studied

  • Diabetic Foot Ulcer (DFU)

Browse trials for

Keywords

  • Diabetic Foot Ulcer
  • DFU
  • PDT
  • Photodynamic Therapy
  • Chlorin E6
  • Phase IIB of Chlorin E6
  • Chlorin E6 Gel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with diagnosis of Diabetes mellitus, with diabetic foot ulcer.
  2. Males and females subject of age 18 years and above.
  3. of less than 12% and random blood sugars of less than 350 mg/dl.
  4. Vitally stable patient with no clinical signs of sepsis, a qSOFA (quick Sepsis-Related Organ Failure Assessment) score of \<2.
  5. ABI (Ankle Brachial Index) 0.7 to 1.2.
  6. Lower extremity ulcer of more than 30 days duration and less than 2 years duration.
  7. Total wound surface area between 0.5 to 20 cm.
  8. Deep wounds extending up to muscles (University of Texas Grade \& Stage 1A, 1B, 2A \& 2B) will be included.
  9. Patients giving written to participate in the study after a full understanding of the implications and constraints of the study protocol.
  10. Understand the content of the ICF, and voluntarily sign the ICF (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed).
  11. The subject can understand the research process and is willing and able to comply with all research proposals and other requirements of the study.
  12. Able to cooperate to complete the scheduled follow-ups till the end of the study

Exclusion criteria

Exclusion Criteria:

  1. The vital signs or physical examination are clinically significantly abnormal as determined by the investigators in screening.
  2. A history of severe allergy (including drugs, vaccines, and foods) or allergy to any component of the experimental product.
  3. Subjects diagnosed with a serious disease, congenital malformation or chronic disease (including but not limited to serious: respiratory disease, cardiovascular disease, serious cerebrovascular disease, kidney disease, serious or uncontrollable diabetes, disease, thrombocytopenic purpura, thalassemia, malignant tumor, hereditary allergic constitution, etc.) that may interfere with the conduct or completion of the study;
  4. Participating in or planning to participate in other clinical trials (drugs or vaccines) within 3 months prior to participating in this study;
  5. Other circumstances considered by the investigator as inappropriate to participate in the study.
  6. Vitally unstable patients with clinical signs and symptoms of sepsis, qSOFA score ≥2.
  7. More than 2 ulcers in the foot and leg.
  8. Deep wounds extending into bone (UoT Criteria any Grade stage C \& D, Grade 3).
  9. Subjects with moderate to severe obstruction on ABI (\<0.7 or >1.3).
  10. Patients with more than 12% and random blood sugar of more than 350 mg /dl.
  11. Subjects with evidence of cardiac disease or heart failure on or echocardiography
  12. Patients with (Estimated Glomerular Filtration Rate) of less than 60 ml/min/1.73 m2.
  13. Pregnant or breast-feeding females or women of not using .
  14. to product/Chlorophyll-driven compounds.
  15. Diagnosed case of porphyria.
  16. Ophthalmological disease requiring slit-lamp examination or Yag-laser within the next 30 days or anti-VEGF therapy/injection.
  17. Patients who do not give written
  18. Subjects unable or unwilling to meet protocol requirements.
  19. Ulcer of non-diabetic etiology, such as venous, arterial, and burn wounds
  20. Ulcer is less than 3 cm in distance from any other ulcer on the same extremity.
  21. Ulcer presents with any of the following: osteomyelitis, exposed bone or gangrene.
  22. Ulcer surface area has decreased > 40% between screening and at randomization (visit 1) as assessed by the imaging system
  23. Has medically documented history of
  24. Has severe protein malnutrition as defined by Serum Albumin \< 2.5 g/dL.
  25. Has serum (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the
  26. Has a medically documented or self-reported history, within the previous 12 months from date of screening visit, of alcohol or substance abuse.
  27. Has received previous treatment with the following during the 60 days prior to screening: agents, radiation, chemotherapy, growth factors at the site of the Ulcer, split- or full-thickness skin graft at the site of the Ulcer, biologically active (or engineered) cellular or acellular product(s) at the site of the study ulcer, investigational drug or device
  28. Has ESR > 70 mm/h and CRP > 100 mg/L at time of screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Group A (IP+PDT+SOC)

    This group will be provided with Standard of Care treatment for DFU, along with IP application and PDT

    Combination Product: Chlorin E6 Gel

  • No intervention
    Group B (SOC Only)

    This group will only receive the Standard of Care treatment for DFU

Interventions

  • Combination productChlorin E6 Gel

    The Group A participants in this study were received Chlorin E6 Gel-mediated Photodynamic Therapy for the management of Diabetic Foot Ulcers

06

What researchers measure

Primary outcomes

  1. Number of adverse event experienced by participants

    Adverse events will include those that are related to study intervention.

    Time frame: 03 months

  2. Efficacy of Chlorin E6-mediated PDT

    To determine the effect of Chlorin E6 on the healing of diabetic foot ulcers, defined by a reduction in size and depth of ulcer

    Time frame: 3 months

  3. Eradication Ratio of Pathogenic Bacteria

    To determine the eradication ratio of pathogenic bacteria through the synergistic effect of local Chlorin E6-mediated Photodynamic Therapy

    Time frame: 03 months

07

Study locations

1 of 1 sites recruiting
  • Creek General Hospital
    Karachi, Sindh 07526, Pakistan
    Recruiting
08

References and documents

Publications

  • Schaper NC, Apelqvist J, Bakker K. The international consensus and practical guidelines on the management and prevention of the diabetic foot. Curr Diab Rep. 2003 Dec;3(6):475-9. doi: 10.1007/s11892-003-0010-4. PubMed 14611743 ↗
  • Oluwole DO, Coleman L, Buchanan W, Chen T, La Ragione RM, Liu LX. Antibiotics-Free Compounds for Chronic Wound Healing. Pharmaceutics. 2022 May 9;14(5):1021. doi: 10.3390/pharmaceutics14051021. PubMed 35631606 ↗
  • Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018 Jan;1411(1):153-165. doi: 10.1111/nyas.13569. PubMed 29377202 ↗
  • Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017 Jun 15;376(24):2367-2375. doi: 10.1056/NEJMra1615439. No abstract available. PubMed 28614678 ↗
  • Borgia F, Giuffrida R, Caradonna E, Vaccaro M, Guarneri F, Cannavo SP. Early and Late Onset Side Effects of Photodynamic Therapy. Biomedicines. 2018 Jan 29;6(1):12. doi: 10.3390/biomedicines6010012. PubMed 29382133 ↗
  • Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011 Jul-Aug;61(4):250-81. doi: 10.3322/caac.20114. Epub 2011 May 26. PubMed 21617154 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 23, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Nov 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07488247
Lead sponsor
United Medical and Dental College
Collaborators
Center for Bioequivalence Studies and Clinical Research
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Apr 2, 2026
Primary completion
Sep 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Apr 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion